1. The fracture risk in
incidentalomas associated with MACS. 2. Minimally invasive and/or
robotic vs open surgery in patients with potentially malignant adrenal mass. 3. Quality of life, mental health,
cognition, and frailty in patients with adrenal incidentalomas, both
non-functioning and the ones with MACS. 4. New biomarkers to identify
patients with clinically relevant cortisol excess.